Overview
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
Associated Conditions
- Cardiovascular Mortality
- Myocardial Infarction
- Stroke
- Thrombosis (Stent Thrombosis)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/12/03 | Not Applicable | Not yet recruiting | |||
2024/11/15 | Phase 4 | Recruiting | |||
2024/11/04 | Phase 1 | Active, not recruiting | |||
2024/10/31 | Phase 4 | Completed | |||
2024/10/22 | Phase 2 | Recruiting | |||
2024/09/19 | Phase 3 | Recruiting | |||
2024/09/11 | Phase 3 | Recruiting | |||
2024/09/11 | Phase 3 | Recruiting | |||
2024/09/11 | Phase 3 | Recruiting | |||
2024/09/05 | Phase 1 | Completed | Tianjin Institute of Pharmaceutical Research Co., Ltd |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | 46708-241 | ORAL | 90 mg in 1 1 | 5/5/2025 | |
| Alembic Pharmaceuticals Inc. | 62332-241 | ORAL | 90 mg in 1 1 | 5/7/2025 | |
| AstraZeneca Pharmaceuticals LP | 0186-0777 | ORAL | 90 mg in 1 1 | 3/22/2024 | |
| Teva Pharmaceuticals, Inc. | 0480-2695 | ORAL | 90 mg in 1 1 | 12/20/2024 | |
| Solco Healthcare U.S., LLC | 43547-657 | ORAL | 90 mg in 1 1 | 12/23/2024 | |
| Cardinal Health 107, LLC | 55154-9618 | ORAL | 90 mg in 1 1 | 11/8/2018 | |
| Oryza Pharmaceuticals, Inc. | 72516-018 | ORAL | 90 mg in 1 1 | 4/15/2025 | |
| AstraZeneca Pharmaceuticals LP | 0186-0776 | ORAL | 60 mg in 1 1 | 3/22/2024 | |
| Amneal Pharmaceuticals NY LLC | 69238-1134 | ORAL | 90 mg in 1 1 | 7/21/2020 | |
| Teva Pharmaceuticals, Inc. | 0480-2688 | ORAL | 60 mg in 1 1 | 12/20/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 12/3/2010 | ||
Authorised | 12/3/2010 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| BRILINTA TABLET 60 MG | SIN15294P | TABLET, FILM COATED | 60 mg | 7/7/2017 | |
| Brilinta Tablet 90 mg | SIN14120P | TABLET, FILM COATED | 90 mg | 3/13/2012 | |
| TICASPAN 90 FILM-COATED TABLETS 90MG | SIN17211P | TABLET, FILM COATED | 90.000mg | 3/26/2025 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Ticagrelor Dispersible Tablets | 国药准字H20253893 | 化学药品 | 片剂 | 4/15/2025 | |
| Ticagrelor Dispersible Tablets | 国药准字H20244044 | 化学药品 | 片剂 | 6/18/2024 | |
| Ticagrelor Dispersible Tablets | 国药准字HJ20200038 | 化学药品 | 片剂 | 9/2/2020 | |
| Ticagrelor Tablets | 国药准字H20193177 | 化学药品 | 片剂 | 6/24/2019 | |
| Ticagrelor Tablets | 国药准字H20213086 | 化学药品 | 片剂 | 1/30/2021 | |
| Ticagrelor Tablets | 国药准字H20203436 | 化学药品 | 片剂 | 8/17/2020 | |
| Ticagrelor Tablets | 国药准字H20205005 | 化学药品 | 片剂 | 7/9/2020 | |
| Ticagrelor Tablets | 国药准字H20227019 | 化学药品 | 片剂 | 2/21/2022 | |
| Ticagrelor Tablets | 国药准字H20233529 | 化学药品 | 片剂 | 5/12/2023 | |
| Ticagrelor Tablets | 国药准字H20223503 | 化学药品 | 片剂 | 7/7/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| TICAGRELOR SANDOZ TABLETS 90MG | N/A | N/A | N/A | 10/12/2023 | |
| TICAROGG 90 TABLETS 90MG | N/A | i & c (hong kong) limited | N/A | N/A | 10/30/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| NOVALANT ticagrelor 90 mg tablet blister pack | 426091 | Medicine | A | 9/26/2024 | |
| TIRELA ticagrelor 90 mg tablet blister pack | 426090 | Medicine | A | 9/26/2024 | |
| BRILINTA ODT ticagrelor 90 mg orodispersible tablet blister pack | 303878 | Medicine | A | 4/4/2019 | |
| Ticagrelor RAN ticagrelor 90 mg tablet blister pack | 437251 | Medicine | A | 12/16/2024 | |
| TICALOR ticagrelor 90 mg tablet blister pack | 377470 | Medicine | A | 10/6/2022 | |
| APO-TICAGRELOR ticagrelor 90 mg tablet blister pack | 377472 | Medicine | A | 10/6/2022 | |
| BRICALOR ticagrelor 90 mg tablet blister pack | 288019 | Medicine | A | 2/21/2023 | |
| PHARMACOR TICAGRELOR ticagrelor 90 mg tablet blister pack | 288021 | Medicine | A | 2/21/2023 | |
| ARX-Ticagrelor ticagrelor 90 mg tablet blister pack | 445790 | Medicine | A | 8/7/2024 | |
| BRILINTA ticagrelor 90 mg tablet blister pack | 167237 | Medicine | A | 6/21/2011 |